AdMeTech FOUNDATION | the manogram® project precision prostate care for every man

Sixth Global Summit
PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

SAVE THE DATES
SEPTEMBER 22-24, 2022

Creating the Future of Patient Care

Scientific Program Draft – July 20, 2022

(The Current Sessions and Presentations are in Eastern Standard Time and Subject to Change)

THURSDAY, SEPTEMBER 22, 2022

8:00AM **WELCOME AND INTRODUCTION**
Faina Shtern, MD, President and CEO, AdMeTech Foundation

8:15AM **SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION**

Moderators:

Jim C. Hu, MD, MPH, Ronald P. Lynch Professor of Urologic Oncology and Professor of Urology, Weill Cornell Medical College, Cornell University; and Attending Urologist, New York-Presbyterian Hospital

Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center, University of Toronto, Canada; and Chair, World Urologic Oncology Federation

Grannum Sant, MD, FRCS, FACS, Professor and Former Chair of Urology, Tufts University School of Medicine; Former Head, Oncology/Urology Medical Affairs, Sanofi, and Rare Genetic Diseases, Genzyme

Clare M. C. Tempany-Afdhal, MB BAO BCh, FACR, FISMRM, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women's Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization

8:30AM ***Topic 1: State of the Art and Future Directions in "Smart" Prostate Cancer Screening – Discussion Chair:*** Sigrid Carlsson, MD, PhD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden

8:30AM *Risk-Stratified Screening and Early Detection of Prostate Cancer in 2022:* Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center

8:36AM *PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50):* Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology

8:42AM Q & A

8:45AM *BARCODE1 Trial: Single-Nucleotide Polymorphisms (SNPs):* Jana McHugh, MB BCh BAO MRCPI FFR RCSI, Clinical Research Fellow, Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology, Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom

8:51AM *IP1-Prostagram Screening Study: Comparing PSA, MRI and Ultrasound:* Hashim Ahmed, MD, Professor and Chair, Division of Surgery, Department of Surgery and Cancer, Imperial College London; Honorary Consultant Urological Surgeon, Imperial Urology, Imperial College Healthcare, NHS Trust, United Kingdom

8:57AM Q & A

9:00AM *ReIMAGINE Study: Feasibility of MRI-based Screening:* Caroline Moore, MD, Professor of Urology, Department of Targeted Intervention, Division of Surgery and Interventional Sciences, University College London, United Kingdom

9:06AM *Perspective from European Union and European Association of Urology on Screening: PSA, Risk Calculator and MRI:* Monique Roobol, PhD, Professor of Decision Making in Urology and Head of Scientific Research Office, Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands

9:12AM Q & A

9:15AM *Göteborg-2 Trial: PSA Screening Followed by MRI:* Jonas Hugosson, MD, Professor and Chief, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden

9:21AM *Clinical Trial of STHLM3 and MRI:* Martin Eklund, PhD, Associate Professor of Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Sweden

9:27AM *ProScreen: A randomized population-based screening trial combining PSA, kallikrein panel and MRI:* Anssi Auvinen, MD, PhD, Professor and Head, Department of Epidemiology, Tampere University, Finland

9:33AM Q & A

9:36AM-10:06AM *Panel Discussion: "Smart" Prostate Cancer Screening*

10:06AM-10:30AM **COFFEE BREAK**

10:30AM ***Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling***

10:30AM *Topic 2A: Current and Emerging Liquid Diagnostics*

10:30AM ***Keynote Address: Clinical Overview****:* E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal

10:40AM Q & A

10:42AM ***Serum microRNA for Diagnosis of Prostate Cancer****:* Shin Egawa, MD, Chairman and Professor, Department of Urology, Jikei University School of Medicine, Japan

10:52AM Q & A

10:54AM *Panel Discussion: Liquid Biomarkers*

11:04AM *Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies*

11:04AM ***Advanced Ultrasound***

11:04AM *Overview:* Ethan Halpern, MD, Professor and Vice Chair for Research; Co-Director, Prostate Diagnostic Center; and Director, Cardiac CT, Thomas Jefferson University

11:14AM *OPTIMUM Trial – Current and Emerging Evidence Supporting 29MHz High- Precision, Real-Time Micro-Ultrasound:* Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel

11:20AM Q & A

11:22AM ***Multi-Parametric (mp)* and *Bi-Parametric (bp) Magnetic Resonance Imaging***

11:22AM *PI-RADS Standardization and Risk Assessment- Recent Advances and Future Plans:* Clare Tempany, MD

11:32AM Q & A

11:34AM *Quality Assessment of Prostate MRI: Impact on the Diagnostic Path:* Jelle Barentsz, MD, PhD, Chair and Professor of Radiology, Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands; and Founding Member and Past-President of the International Cancer Imaging Society, and Past-President of the European Society of Urogenital Radiology

11:44AM Q & A

11:46AM ***MRI-targeted Biopsy of the Prostate for Improved Tissue Sampling:*** Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School

11:58AM Q & A

12:00AM ***PRIMARY Trial – The Role of Integrated Molecular and MRI Imaging Prior to Biopsy:*** Louise Emmett, MD, Professor and Director, Department of Theranostics and Nuclear Medicine, St. Vincent Hospital; and Clinical Research Leader, Garvan Institute of Medical Research, Sydney, Australia

12:10PM Q & A

12:12PM ***How the Addition of Multiparametric MRI has Changed a Private Practice Setting in Prostate Screening:*** Richard G. Barr, MD, PhD, FACR, FSRU, Professor of Radiology, Northeastern Ohio Medical University

12:18PM Q & A

12:20PM *Panel Discussion: Imaging Modalities and Targeted Biopsies*

12:32PM ***Topic 3: Transperineal Prostate Biopsy – Current and Future Clinical Role****:* Jim C. Hu, MD, MPH

12:42PM Q & A

12:44PM ***Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer 2022****:* Preston Sprenkle, MD

12:54PM Q & A

12:56PM-1:08PM **General Discussion –** Moderators, Speakers and Mark Katz, MD, Assistant Professor of Surgery, Boston University School of Medicine

1:12PM-2:52PM **LUNCH BREAK**

2:52PM **SESSION II. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (PART 1)**

Moderators:

Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF

Eric Klein, MD, Fellow, Stanford Distinguished Careers Institute; and Emeritus Professor and Chairman, Glickman Urological and Kidney Institute at Cleveland Clinic (TBC)

Jelle Barentsz, MD, PhD

3:22PM ***Topic 1: Liquid Markers – Proteomics and Germline Genome:*** Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA

3:32PM Q & A

3:34PM ***Topic 2: Tissue-Based Genetic Cancer Profiling Overview:*** Matthew R. Cooperberg, MD, MPH

3:44PM Q & A

3:46PM ***Topic 3: Pathology Overview:*** Thomas M. Wheeler, MD, Director of Surgical Pathology and Cytopathology, Sagis Diagnostics; Distinguished Emeritus Professor and Immediate Past Chair, Department of Pathology & Immunology, Baylor College of Medicine

3:56PM Q & A

3:58PM-4:22PM **COFFEE BREAK**

4:22PM ***Topic 4: Current and Future Directions in Risk Assessment:*** **Should Gleason 6 (GG1) be Considered Cancer?**
Scott Eggener, MD, Bruce and Beth White Family Professor of Surgery and Radiology, Vice Chair, Section of Urology and Director, High Risk and Advanced Prostate Cancer Clinic, University of Chicago

4:32PM Q & A

4:34PM *Panel Discussion: Liquid Markers and Tissue Analysis*

4:42PM ***Topic 5: In Vivo Imaging***

4:42PM *Topic 5A: Prostate MRI*

4:42PM ***Clinical Role of MRI in Staging and Risk Assessment:*** Peter Choyke, MD, Director, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health

4:52PM Q & A

4:54PM ***Prostate Cancer Visibility on MRI: Histopathologic and Genomic Considerations****:* Andrei Purysko, MD, Clinical Assistant Professor of Radiology, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Staff, Section of Abdominal Imaging and Nuclear Radiology, Imaging Institute, Cleveland Clinic; Staff, Glickman Urological and Kidney Institute, Cleveland Clinic

5:04PM Q & A

5:06PM *Topic 5B: Molecular Imaging:* Andrei H. Iagaru, MD, FACNM, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program Stanford University

5:16PM Q & A

5:18PM *Panel Discussion: MRI and Molecular Imaging*

5:23PM - 6:00PM **GENERAL DISCUSSION**

FRIDAY, SEPTEMBER 23, 2022

8:00AM **SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (PART 2))**

Moderators:

Andrei H. Iagaru, MD

Adam Kibel, MD, Elliott Carr Cutler Professor of Surgery, Harvard Medical School; Chief of Urology, Brigham and Women's Hospital and Dana-Farber Cancer Institute

Kelvin A. Moses, MD, PhD, FACS, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel

Lalitha K. Shankar, MD, PhD, Chief, Clinical Trials Branch, Cancer Imaging Program, National Cancer Institute (NCI)

8:00AM *Topic 5C: Molecular and Multi-Modality Imaging for Visualization and Staging of the Initial and Recurrent Disease*

8:00AM ***Overview of Non-Invasive and Intraoperative PSMA Imaging****:* Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum der Isar, Technical University of Munich, Germany

8:10AM Q & A

8:12AM ***MRI and Biochemical Recurrence:*** Valeria Panebianco, MD, Associate Professor of Radiology, "Sapienza" – University of Rome; Responsible, Advanced MR & CT Imaging Division & Coordinator, Prostate Unit, Rome, Italy

8:22AM Q & A

8:24AM *Panel Discussion: Diagnosis of Recurrence*

8:34AM ***Topic 6: Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and Radiogenomics:*** Mohummad Minhaj Siddiqui, MD, Associate Professor of Surgery, Director of Urologic Oncology and Robotic Surgery, University of Maryland Medical System, and Chief of Urology, Baltimore VA Medical Center; and Participant, US Vice President Joseph Biden's Cancer Moonshot Program

8:44AM Q & A

8:46AM-9:15AM **COFFEE BREAK**

9:15AM ***Topic 7: Integration of Precision Diagnosis and Precision Treatment***

9:15AM *Topic 7A: Featured Presentation on the NCI Clinical Trials in Prostate Cancer Imaging and Theranostics:* Lalitha K. Shankar, MD, PhD

9:25AM Q & A

9:27AM *Topic 7B: Integrated Diagnostics (Radiogenomics) and Active Surveillance: Patient and Monitoring:* Sanoj Punnen, MD, MAS, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Vice Chair of Research, Department of Urology Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine

9:37AM Q & A

9:39AM *Topic 7C: Selection and Monitoring of Image-Targeted Minimally Invasive Treatment:* Fiona Fennessy, MB, Bch, PhD, Associate Professor of Radiology, Harvard Medical School; Faculty Radiologist, Brigham & Women's Hospital; Program Director, Cancer Imaging Fellowship Program; and Institute Physician, Dana-Farber Cancer Institute

9:49AM Q & A

9:51AM *Topic 7D: Surgical Treatment:* Adam Feldman, MD, MPH, Urologist, Massachusetts General Hospital; Assistant Professor of Surgery, Harvard Medical School; and Director, Combined Harvard Urologic Oncology Fellowship

10:01AM Q & A

10:03AM *Topic 7E: Radiation Oncology Perspective:* Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University

10:13AM Q & A

10:15AM *Topic 7F: NCCN Guidelines for Treatment of Localized Prostate Cancer:* Kelvin A. Moses, MD, PhD

10:25AM Q & A

10:27AM *Panel Discussion: Integration of Precision Diagnosis and Treatment*

11:30AM-1:30PM **LUNCH BREAK**

1:30PM **SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER**

Moderators:

Peter Choyke, MD

David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program

Alan Pollack, MD, PhD, Professor and Chairman of Radiation Oncology, University of Miami Miller School of Medicine; and Service Chief, Radiation Oncology, Jackson Memorial Hospital

Robert E. Reiter, MD, MBA, Bing Professor in Prostate Cancer; Director, Prostate Cancer Program and Chief, Division of Urologic Oncology; Assistant Dean, Bioentrepreneurship; Department of Urology, David Geffen School of Medicine at UCLA Institute of Urologic Oncology

2:00PM ***Keynote Address: Precision Oncology for Prostate Cancer:*** Charles J. Ryan, M.D, Professor of Medicine, B.J. Kennedy Chair in Clinical Medical Oncology, University of Minnesota; and President and CEO, Prostate Cancer Foundation

2:10PM Q & A

2:12PM ***Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease***

2:12PM *Topic 1A: An Update on the Advanced Prostate Cancer Consensus Conference:* Robert E. Reiter, MD, MBA

2:22PM Q & A

2:24PM *Topic 1B: Review of the New Standard in Treatment and Related Decision Tree: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors:* Marc Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; and Special Advisor, Oncologic Drugs Advisory Committee of the FDA

2:34PM Q & A

2:36PM *Topic 1C: Novel Targeted Treatment and Its Integration with Precision Diagnostics:*

2:36PM ***Current and Emerging Role of the Detection and Treatment of Somatic or Germline Homologous Recombination Repair (HRR) Gene Mutations in mCRPC****:* Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University

2:46PM Q & A

2:48PM ***Circulating Tumor Cells, DNA, RNA and Treatment Planning:*** David Nanus, MD

2:58PM Q & A

3:00PM *Topic 1D: Epigenetic Modulations and Lineage Plasticity:* Himisha Beltran, MD, Associate Professor of Medicine, Harvard Medical School and Director of Translational Research, Department of Medical Oncology, Dana-Farber Cancer Institute

3:10PM Q & A

3:12PM *Topic 1E: Immunotherapy: Why do we (mostly) fail?:* Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors

3:22PM Q & A

3:24PM *Topic 1F: Radiation Treatment and Its Integration with Precision Diagnostics:* Alan Pollack, MD

3:34PM Q & A

3:36PM *Topic 1G: Phase 3 VERACITY Clinical Trial of Sabizabulin for the Treatment of Men with mCRPC who Progressed on an Androgen Receptor Targeting Agent:* Speaker TBA

3:42PM Q & A

3:44PM *Panel Discussion: Standard and Emerging Treatment*

3:54PM – 4:14PM **COFFEE BREAK**

4:14PM ***Topic 2: Molecular and Multi-Modality Imaging and Theranostics***

4:14PM *Topic 2A: PSMA Imaging – Emerging Clinical Utility:* Thomas Hope, MD, Associate Professor of Radiology and Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging; Chair of the Cancer Center's Molecular Imaging & Radionuclide Therapy Site Committee, University of California, San Francisco; Chief of Nuclear Medicine at the San Francisco VA Medical Center

4:24PM Q & A

4:26PM *Topic 2B: Theranostics*

4:26PM ***An overview of PSMA PET for improving patient selection for and outcomes of LuPSMA therapy****:* Jeremie Calais MD, MSc, Associate Professor, Department of Molecular and Medical Pharmacology; Director, UCLA Theranostics Program, Ahmanson Translational Theranostics Division, University of California, Los Angeles

4:36PM Q & A

4:38PM ***PYLARIFY® (piflufolastat F 18) Injection PET/CT Imaging in Prostate Cancer Patients*****:** Ashley Ross, MD, PhD, Associate Professor of Urology, Feinberg School of Medicine, Northwestern Medicine

4:50PM Q & A

4:52PM ***Current State of the Art and Future Vision in Theranostics:*** Philip Koo, MD, Chief of Diagnostic Imaging and Physician Executive, Northwest Region, Banner MD Anderson Cancer Center

5:02PM Q & A

5:04PM *Panel Discussion: Molecular Imaging and Theranostics*

5:30PM - 6:30PM **GENERAL DISCUSSION**

SATURDAY, SEPTEMBER 24, 2022

8:00AM **SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: *Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes***

Moderators:

David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York

Raja B. Khauli, MD, FACS, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign

Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine

Sadhna Verma, MD, Professor of Radiology, University of Cincinnati College of Medicine

Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine

8:30AM *Overview:* Jurgen Fütterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen, and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands

8:40AM Q & A

8:42AM *Current Clinical Trials:* John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine

8:52AM Q & A

8:54AM *MRI Standardized Reporting for Focal Therapy Planning and Follow-up:* Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University

9:04AM Q & A

9:06AM *Micro-Ultrasound and Focal Laser Ablation at the University of Toronto:* Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada

9:16AM Q & A

9:18AM *Image-Guided Laser Ablation – Experience at the University of Chicago:* Aytekin Oto, MD, Professor and Chairman of Radiology, University of Chicago

9:28AM Q & A

9:30AM – 10:00AM **COFFEE BREAK**

10:00AM *Image-Guided High Intensity Focal Ultrasound – Recent Clinical Trials:* Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA

10:10AM Q & A

10:12AM *Targeted Ablation of Prostate Cancer: UTSW's Experience with the TULSA Procedure:* Kenneth Goldberg, MD, Assistant Professor, Department of Urology at UT Southwestern Medical Center

10:18AM Q & A

10:20AM *Sight and Switch off: Nerve Density Visualization for Interventions Targeting Prostate Cancer:* Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China

10:30AM Q & A

10:32AM *Urologic Perspective on Clinical Utility and Outcomes: The Importance of Close Collaboration between Radiology and Urology:* Geoffrey Sonn, MD, Assistant Professor of Urology and Radiology, Stanford University School of Medicine

10:42AM Q & A

10:44AM *Panel Discussion: Image-Guided Treatment*

11:00AM-1:00PM **LUNCH BREAK**

1:00PM **PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT**

Moderators:

Paul Boutros, PhD, MBA

Arnold C Cinman, MD, FACS, Tower Urology, Attending Urologist, Cedars-Sinai Medical Center

Masoom Haider, MD, Professor of Radiology, University of Toronto; Senior Clinician Scientist, Lunenfeld Tanenbaum Research Institute; Director, Machine Learning and Radiomics Lab; and Director, Sinai Health System Research MRI, Canada

Michael H. Johnson, MD, Vice Chief of Urology, Washington University, St. Louis

Christoph Wald, M.D., Ph.D., M.B.A., F.A.C.R., Professor and Chairman of Radiology, Lahey Hospital and Medical Center, Tufts University Med School; and Chair, Informatics Commission, American College of Radiology

1:00PM *Personalization of Prostate Cancer Care through Integration of Data:* Ilya Gipp, MD, PhD, Oncology Solutions Subject Matter Expert, Philips

1:22PM Q & A

1:24PM *Radiologic Perspective on the Emerging and Potential Role of Machine Learning:* Masoom Haider, MD

1:34PM Q & A

1:36PM *Personalized And Population Specific Computational Imaging Approaches for Prostate Cancer Diagnosis And Prognosis:* Rakesh Shiradkar, PhD, Research Assistant Professor, Biomedical Engineering, Case Western Reserve University, Member, Case Comprehensive Cancer Center

1:46PM Q & A

1:48PM *Development of New Approaches Using Artificial Intelligence for Segmentation of Dominant Index lesion in Prostate Cancer:* Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan Kettering Cancer Center and Harini Veeraraghavan, Ph.D, Associate Attending Computer Scientist, Department of Medical Physics, Memorial Sloan Kettering Cancer Center

1:58PM Q & A

2:00PM *Panel Discussion: Bioinformatics, Artificial Intelligence and Machine Learning*

2:10PM – 2:30PM **COFFEE BREAK**

2:30PM **PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER**

Moderators:

Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health

Quoc-Dien Trinh, MD, Co-Director, Dana-Farber/Brigham and Women's Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School

2:30PM *Overview of Emerging Data:* Quoc-Dien Trinh, MD

2:40PM Q & A

2:42PM *Current State of Knowledge – Genomics and Health Disparities:* Yaw Nyame, MD, MS, MBA, Assistant Professor, Department of Urology, University of Washington; Program Lead, Office of Community Outreach and Engagement and Affiliate Assistant Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center

2:52PM Q & A

2:54PM *Current and Emerging Approaches to Prostate Cancer Equity:* Adam B Murphy, MD, MBA, MSCI

3:04PM Q & A

3:06PM *Panel Discussion: Health Disparities*

3:30PM-4:00PM **Presentation of Winning Abstracts**

4:00PM-6:00PM **SUMMARY PANEL DISCUSSION – SUMMIT HIGHLIGHTS**

6:00PM ***ADJOURN***